The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of 25-gene panel testing and integrated risk management tool on medical management in hereditary cancer syndrome evaluation.
Lucy R. Langer
Consultant or Advisory Role - Myriad Genetics
Honoraria - Myriad Genetics
Laurie Korst
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Larry J. Geier
Honoraria - Myriad Genetics
Jennifer Saam
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Kelsey Moyes
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Lee Steven Schwartzberg
Consultant or Advisory Role - Myriad Genetics